Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins
Executive Summary
Lilly will seek FDA approval in the second half of 2017 for CGRP inhibitor galcanezumab based on three positive Phase III studies – within months of a filing for Amgen's and Novartis's CGRP inhibitor erenumab.